Happi-IT Capsule PR is a combination pharmaceutical formulation containing Rabeprazole 20 mg and Itopride 150 mg, designed for the effective management of gastrointestinal disorders. Rabeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting ulcer healing. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, which facilitates gastric emptying and alleviates symptoms of functional dyspepsia. This synergistic combination is indicated for the treatment of conditions such as gastroesophageal reflux disease (GERD), functional dyspepsia, gastritis, and peptic ulcer disease where both acid suppression and improved gastric motility are desired. Happi-IT Capsule PR is typically administered orally once daily before meals, with dosage adjustments based on clinical response and tolerability. The combination therapy offers improved symptom relief, enhanced mucosal healing, and better patient compliance compared to monotherapy. Caution is advised in patients with hepatic impairment, and it should be used under medical supervision, considering potential drug interactions and contraindications. Regular monitoring is recommended to assess therapeutic efficacy and detect any adverse effects.